GDC-0834, a Bruton's tyrosine kinase inhibitor investigated as a potential treatment for rheumatoid arthritis, was previously reported to be extensively metabolized by amide hydrolysis such that no measurable levels of this compound was detected in human circulation following oral administration. In vitro studies in human liver cytosol determined GDC-0834 was rapidly hydrolyzed with CL int of 0.511 mL/min/mg protein. 
Introduction GDC-0834 is a potent, selective, and reversible ATP-competitive small molecule inhibitor of Bruton's tyrosine kinase (BTK) that was under consideration as a therapeutic agent for rheumatoid arthritis (Liu et al., 2011a; Liu et al., 2011b) . One liability for GDC-0834 was the low confidence in the human pharmacokinetic prediction based on the species-dependent metabolism, with amide hydrolysis being more predominant in human than other pre-clinical species. However, despite the uncertainty in the human clearance prediction, there was a high level of interest in a BTK inhibitor for clinical
evaluation. An investigational new drug strategy was initiated in which GDC-0834 was rapidly advanced to a single-dose human clinical trial study. Exploratory clinical studies established that after oral administration of 35 and 105 mg GDC-0834 to healthy volunteers, limited exposure of this drug was observed in circulation (<1 ng/mL in most plasma samples). This was attributed primarily to metabolism, with the majority of drugrelated circulating material being the aniline metabolite M1 (Fig. 1) . At 35 mg, the mean highest observed plasma concentration (C max ) of M1 was 142 ng/mL; at 105 mg, the mean C max of M1 was 390 ng/mL (Liu et al., 2011b) .
In contrast to humans, the extensive metabolism of GDC-0834 was not evident in preclinical species, as GDC-0834 was orally bioavailable following oral administration to mice, rats, dogs, and monkeys. In plasma of preclinical species, M1 was minor and the percent exposure ratios of M1 AUC / parent AUC were 9.3% (SCID mice), 1.5% (rats),
5 hepatocytes predicted hydrolysis as the route of metabolism in humans and indicated significant differences in amide hydrolysis rates between humans and other preclinical species (Liu et al., 2011b) . This specific GDC-0834 to M1 biotransformation was much more pronounced in human liver fractions than those of preclinical species.
Here we investigated the enzyme(s) involved in the amide hydrolysis of GDC-0834.
Preliminary in vitro metabolism experiments using various liver fractions revealed that soluble enzyme(s) present in human liver cytosol (HLC) mediated the amide hydrolysis of GDC-0834. Therefore, HLC was chosen over human liver microsomes and hepatocytes since it contained the soluble enzyme(s) to facilitate fractionation and MSproteomics analysis. A series of kinetic experiments with probe substrates and chemical inhibitors of aldehyde oxidase (AO), carboxylesterase (CES), and xanthine oxidase (XO), as well as in silico modelling studies of GDC-0834 were conducted. min. Reactions were terminated using acetonitrile containing the internal standard (100 µL) and centrifuged for 10 min at 2,000g. The supernatants (100 µL) were removed, combined with water (200 µL), and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify the relative abundance of M1 formed from GDC-
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Mass Spectrometry Proteomics and Correlation Profiling. Mass spectrometry proteomics and correlation profiling were used to help identify potential candidate enzymes responsible for conversion of GDC-0834 to M1. A series of seven fractions (fractions 25 -31) containing measurable amide hydrolytic activity and one fraction (fraction 24) lacking activity were loaded onto a series of lanes on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-12% Bis/Tris gradient gel run in MOPS buffer. Proteins were partially separated, subjected to in-gel trypsin digestion, and peptides analyzed by LC-MS/MS on an LTQ-Orbitrap XL mass spectrometer as described previously (Phu et al., 2011; Sheng et al, 2012) . Precursor ions were analyzed in high resolution (resolving power of 60K) in the Orbitrap and MS/MS spectra were collected in the ion trap using data-dependent acquisition. MS/MS were searched using Mascot against a concatenated target-decoy database comprised of forward and reverse sequence of human proteins from Uniprot and common contaminants with a 50 ppm precursor ion tolerance. Peptide spectral matches were filtered to a 1% false discovery rate using linear discriminant analysis. Pearson correlations were determined for each protein using the spectral count data relative to the Optimized incubation times in HLC and DLC were 10 min and 60 min, respectively.
Incubations (100 µL) were terminated by protein precipitation with addition of acetonitrile containing the internal standard (200 µL). All samples were centrifuged for 10 min at 2,000g, the supernatants removed, diluted 1:2 (v/v) with 0.1% FA in water, and analyzed by LC-MS/MS. Standard curves of the M1 standard prepared in each matrix were used, with a lower limit of quantitation 0.01 µM, to quantify the amount of M1 formed and estimate the maximum rate of M1 formation (V max ) and the MichaelisMenten constant (K m ) using nonlinear regression analysis within GraphPad Prism (GraphPad Software Inc., La Jolla, CA) using the Michaelis-Menten equation:
where Y is enzyme velocity and X is substrate concentration. 3ZYV) (Coelho et al., 2012) . Induced-fit docking was used to place DACA into the active site of AO. Sequence alignment used the ClustalW program and required no user input due to the high homology (79% homology) of the two primary sequences. For the portions of the mouse structure lacking sufficient electron density, the human enzyme was modelled using the energy-based method in Prime. However, residues 168-200 were not able to be replaced and were excluded in the model. Modelling was done with
Schrödinger's Prime module to generate a protein structure followed by the induced fit docking workflow using DACA as a ligand to refine amino acid residues within 5 Å of the DACA ligand. Glide docking energies were assessed for DACA, zaleplon, RS-8359, XK-469, and GDC-0834. The structure for each of these compounds (except GDC-0834) has been reported (Alfaro and Jones, 2008; Jones and Korzekwa, 2013) . 2A ). Pearson correlations were determined for each identified protein relative to normalized metabolic activity ( Fig. 2A-B ). Among the top candidates, AO was identified and displayed a pattern of peptide spectral matches that tightly correlated with amide hydrolysis activity (r 2 =0.9708) ( Fig. 2A-B ).
Results
Mass Spectrometry Proteomics and Correlation Profiling (or Identification of Aldehyde Oxidase in HLC by Correlation Profiling
Kinetic Formation of M1 in HLC and DLC. The kinetic parameters describing the metabolism GDC-0834 to M1 were determined by incubating parent compound with HLC or DLC. Amide hydrolysis in humans was found to be more efficient than in dogs, with V max of 409 ± 29 compared to 20.3 ± 9.6 pmol/min/mg protein, K m of 0.800 ± 0.027 compared to 63 ± 5 μ M, and intrinsic clearance (V max /K m ) of 0.511 compared to 0.00025 mL/min/mg protein in humans and dogs, respectively (Supplemental Fig. 1A and 1B).
Formation of M1 in Fresh Blood and Plasma. The formation of M1 over time
from GDC-0834 (0.8 μM initial concentration) was determined in fresh blood and plasma collected from human, rat, mouse, dog, and monkey. A time-dependent formation of M1 was observed in human, rat, and mouse blood and plasma. In dog and monkey, a timedependent formation of M1 was observed in plasma, but levels in blood were below the limit of quantification (<0.001 μ M) (Fig. 3) . The amounts of formation of M1 were more pronounced in mouse blood and plasma with 0.016 and 0. 
Inhibition of AO-and CES-mediated Metabolism by M1 and M2. The inhibitory
properties of M1 and M2 were examined in HLC. M1 and M2 were weak inhibitors of AO-and CES-mediated metabolism of phthalazine and CPT-11, respectively. The IC 50 values were >10 μ M (Supplemental Fig. 2A-D) . GDC-0834 was rapidly advanced to a single-dose human clinical trial to investigate its pharmacokinetic parameters due to other advantageous properties. Unfortunately, following oral administration of GDC-0834 to humans, little to no parent compound was detected due to extensive metabolism. Amide hydrolysis of GDC-0834 and subsequent M1 formation was the major metabolic pathway responsible for its high clearance in the clinic (Fig. 1) . The enzyme(s) responsible for the amide hydrolysis was (were) unknown prior to clinical pharmacokinetic studies. Using HLC, GDC-0834 was observed to be a substrate for enzyme(s) in this subcellular fraction with a relatively low K m (0.8 µM) and relatively high rate of amide hydrolysis (approximately 400 pmol/min/mg).
Inhibition of AO-mediated
The most obvious enzymes considered as candidates for metabolizing GDC-0834 were esterases and amidases, which are capable of hydrolyzing amide bonds. These enzymes include carboxylesterases, cholinesterases, organophosphatases, and amidases/peptidases, where cholinesterases and aminopeptidases are most efficient in hydrolyzing the amide bonds of marketed drugs (Uetrecht and Trager, 2007) and the most active hydrolases in human small intestine and liver (Taketani et al., 2007) . In vitro inhibition studies in human liver microsomes, using general inhibitors of esterases and amidases, failed to implicate these as the hydrolytic enzymes responsible for the metabolism of GDC-0834 (Liu et al., 2011b) .
Preliminary in vitro metabolism experiments using various liver fractions revealed that soluble enzyme(s) present in HLC mediated the amide hydrolysis of GDC-0834. Therefore, HLC was chosen over human liver microsomes and hepatocytes since it contained the soluble enzyme(s) to facilitate fractionation and MS-proteomics analysis. In an attempt to identify the
1 7 enzyme(s) responsible for the amide hydrolysis of GDC-0834, HLC was fractionated and subjected to proteomic correlation profiling analogous to methods employed for matching kinases with their respective substrates (McAllister and Gygi, 2013) . Proteomic analysis of the fractions was then correlated to the rate of hydrolysis of GDC-0834 (Fig. 2) . 1 8 0834 were used compared to that of HLC. These data highlight the extensive capability and efficiency of GDC-0834 hydrolysis in humans.
GDC-0834 was metabolically stable in whole blood and plasma, which suggested limited contribution of these matrices to the total clearance in vivo (Liu et al., 2011b) . In addition, these studies allowed for the assessments of 1) hydrolysis of GDC-0834 by a hydrolase (presumably CES) since this enzyme (but not AO) is reported to be present in plasma and blood (McCracken et al., 1993; Sharma et al., 2011; Beedham 2002) and 2) the specificities of the various AO inhibitors. In blood and plasma, the loss of GDC-0834 was minimal coupled with little M1
formation (<2% by 180 min) in all species, except in mouse plasma (15% by 180 min) (Fig. 3) .
Chemical inhibition studies in human plasma confirmed the specificities of the AO inhibitors used to implicate AO in HLC. In human plasma, which contains CES but not AO, the AO inhibitors did not inhibit the formation of M1, whereas BNPP and loperamide did. These data support the findings of AO involvement in HLC using AO chemical inhibitors, and implicates AO-mediated hydrolysis in HLC, a matrix which contains both AO and CES.
In addition to the potent inhibition of GDC-0834 metabolism by AO inhibitors, GDC-0834 also inhibits the metabolism of several known AO substrates carbazeran, DACA, O With the use of in silico modelling, it is possible to speculate that the amide bond of GDC-0834 could be coordinated in such a way to be attacked by the hydroxymolybdenum for the initial step to form a tetrahedral intermediate (Fig. 6 ). This step requires a nucleophilic hydroxyl moiety. While the oxidized hydroxymolybdenum species is capable of nucleophilic attack as is evident by the nucleophilic aromatic substitution normally catalyzed by this reaction,, we propose that Mo IV oxidative state is more suited for this reaction due to higher electron density.
This would require build-up of the Mo IV oxidative state in much the same way that AO-mediated reductions of compounds, such as nitrites, need a substrate to initially be oxidized (Weidert et al., 2014 ( 1 ) : 
